Focal Therapy for Prostate Cancer: Is It Being Oversold?

Despite growing enthusiasm for this minimally invasive option for some men with prostate cancer, focal therapy is still not FDA-approved for prostate cancer and comes with high out-of-pocket costs.

Related Keywords

Maryland ,United States ,Baltimore ,Florida ,University Of Chicago ,Illinois ,The Cleveland Clinic ,Ohio ,Leesburg ,Chicago ,Norway ,Cleveland ,United Kingdom ,Cleveland Clinic ,Bahamas ,The ,London ,City Of ,American ,Sloan Kettering ,Marvin George ,Hashim Ahmed ,William Catalona ,Daniel Spratt ,Jonathan Shoag ,University Hospitals Seidman Cancer Center ,University Hospitals ,Case Western Reserve University In Cleveland ,Northwestern University Feinberg School Of Medicine ,Imperial College London ,Aetna ,American Urological Association ,Johns Hopkins School Of Medicine ,Case Western Reserve University School Of Medicine ,Richard Lafrate ,Mayo Clinic ,Memorial Sloan Kettering ,Blue Cross Shield ,Case Western Reserve University ,Case Western Reserve University School ,Johns Hopkins School ,Northwestern University Feinberg School ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Of The Prostate ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Prostatic ,Metastasis ,Etastatic Carcinoma ,Metastatic Cancer ,Metastases ,Biologic Therapy ,Iologics ,Prostate Specific Antigen ,Sa ,Sa Prostate Specific Antigen ,Ultrasonography ,Ultrasound ,Monogram ,Clinical Guidelines ,Guidelines ,